Index Ventures

Index Ventures has added two senior executives to its life science practice. Kevin Johnson and Gianni Garotta join as executives in residence. In addition Ennio Ongini has taken on the role of venture adviser within the team. Kevin Johnson was most recently with Cambridge Antibody Technologies, where he was a member of the start-up team, chief technology officer and member of the board. He led the team that produced Humira, the first fully human therapeutic antibody and was part of the management team that floated CAT Plc on the London Stock Exchange in 1997. Johnson's direct entrepreneurial experience will prove invaluable in creating investment opportunities as well as providing insights to Index's portfolio companies. Gianni Garotta has a combined record of academia, pharmaceutical and biotech experience. He was most recently VP of academic collaborations at Serono. Prior to this, he was head of both the interferon and the antibody groups at Roche as well as head of biology at Human Genome Sciences. Garotta’s experience in identifying, evaluating, and negotiating the transfer of assets from academia as well as his background in drug development and immunology make him an exceptional asset to the team. Ennio Ongini, alongside his current role as head of discovery at Nicox, will be acting as a venture adviser to Index. He has extensive drug discovery experience - particularly in the areas of CNS and cardiovascular - and contributed significantly to the identification and development of marketed drugs such as Claritin, Doral and Felbatol.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH